Inventiv Health — Q4 2015 Earnings Presentation
17 slides from Inventiv Health's earnings presentation, Mar 22, 2016
Slide 1: inVentiv Health Fourth Quarter 2015 Earnings Presentation
inVentiv Health Fourth Quarter 2015 Earnings Presentation March 24, 2016 Exhibit 99.1
Slide 2: Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We caution readers that certain im
Slide 3: Quarterly Highlights
Quarterly Highlights Record financial performance in Q4 built on recent momentum Organic net revenue(1) growth of 16% (13% reported net revenue growth) Adjusted EBITDA(2) growth of 38% to $87mm Full year organic net revenue(1) and Adjusted EBITDA(2) growth of 13% and 34%, respectively Actively ident
Slide 4: Clinical Update
Clinical Update Performance accelerated in Q4 Organic net revenue(1) growth of 16% (13% reported net revenue growth) Adjusted EBITDA(2) growth of 65% Backlog conversion accelerated on full service projects Growth was strongest in core, complex therapeutic areas Miami clinic recruited patients for fi
Slide 5: Commercial Update
Commercial Update Continued momentum in Q4 Organic net revenue(1) growth of 16% (13% reported net revenue growth) Adjusted EBITDA(2) growth of 15% Selling Solutions and Communications business strength continued Significant demand and pipeline for outsourced commercial offering Accelerating adoption
Slide 6: Consolidated inVentiv Health Q4 2015 Financial Update
Consolidated inVentiv Health Q4 2015 Financial Update The sum of the segments do not reconcile to Consolidated inVentiv Health due to the elimination of intersegment revenue which totaled approximately $4.3 million for the three months ended 12/31/2015, approximately $13.5 million for the year ended
Slide 7: Clinical Performance
Clinical Performance Net Revenues(1) ($ millions) Adjusted EBITDA(2) ($ millions) The sum of the segments do not reconcile to Consolidated inVentiv Health due to the elimination of intersegment revenue which totaled approximately $4.3 million for the three months ended 12/31/2015, approximately $13.
Slide 8: Clinical Backlog
Clinical Backlog Net Book-to-Bill = Net New Wins / Revenue Earned. Total Clinical Serviceable Backlog Q4 2015 LTM ($ millions) Beginning Backlog $1,982 $1,860 + Net New Wins $326 $1,145 - Revenue Earned ($250) ($948) Ending Backlog $2,058 $2,058 Net Book-to-Bill (1) 1.30x 1.21x
Slide 9: Commercial Performance
Commercial Performance Net Revenues(1) ($ millions) Adjusted EBITDA(2) ($ millions) The sum of the segments do not reconcile to Consolidated inVentiv Health due to the elimination of intersegment revenue which totaled approximately $4.3 million for the three months ended 12/31/2015, approximately $1
Slide 10: Adjusted Free Cash Flow and Net Leverage
Adjusted Free Cash Flow and Net Leverage Adjusted Free Cash Flow(1) ($ millions) Net Leverage(2) ($ millions) Free Cash Flow = Adjusted EBITDA – Capex +/- Changes in NWC. Leverage = Total Debt – Cash, divided by LTM adjusted EBITDA.
Slide 11: Appendix
Appendix a iventiv > 11 ©2015 AllRights Reserved | CONFIDENTIAL Health
Slide 12: EBITDA Reconciliation: Quarter and Last Twelve Months Ended December 31, 2015
For the Quarter and Last Twelve Months Ended December 31, 2015 ($ millions) Adjusted EBITDA Reconciliation Note: Please refer to slide 17 for footnotes.
Slide 13: EBITDA Reconciliation: Quarter Ended December 31, 2015
For the Quarter Ended December 31, 2015 ($ millions) Adjusted EBITDA Reconciliation Note: Please refer to slide 17 for footnotes.
Slide 14: EBITDA Reconciliation: Quarter Ended December 31, 2014
For the Quarter Ended December 31, 2014 ($ millions) Adjusted EBITDA Reconciliation Note: Please refer to slide 17 for footnotes.
Slide 15: EBITDA Reconciliation: Twelve Months Ended December 31, 2015
For the Twelve Months Ended December 31, 2015 ($ millions) Adjusted EBITDA Reconciliation Note: Please refer to slide 17 for footnotes.
Slide 16: EBITDA Reconciliation: Twelve Months Ended December 31, 2014
For the Twelve Months Ended December 31, 2014 ($ millions) Adjusted EBITDA Reconciliation Note: Please refer to slide 17 for footnotes.
Slide 17: Adjusted EBITDA Footnotes
Adjusted EBITDA Footnotes (c) Represents non-cash adjustments resulting from the revaluation of certain items such as deferred revenue and deferred rent recognized in connection with our acquisitions that affect the comparability of our operational results and for which an adjustment is made consist